USSTOCK.TODAY
Market Closed
Log in Sign up

X.T.L. Biopharmaceuticals Ltd ADR(XTLB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

XTLB
XTLB
X.T.L. Biopharmaceuticals Ltd ADR
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.48
-0.06 ▼ -3.90%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.48
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -Insider Own ⓘ 2.46%Shs Outstand ⓘ 4.3MPerf Week ⓘ -9.76%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 4.3MPerf Month ⓘ -20.86%
Enterprise Value ⓘ -PEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 1.23%Short Float ⓘ 0.1%Perf Quarter ⓘ -46.76%
Income ⓘ -P/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ -99.71%Short Ratio ⓘ 0.57Perf Half Y ⓘ -40.56%
Sales ⓘ -P/B ⓘ -EPS next 5Y ⓘ -ROA ⓘ -Short Interest ⓘ 0.00MPerf YTD ⓘ -36.21%
Book/sh ⓘ -P/C ⓘ -EPS past 3/5Y ⓘ 29.65% 31.74%ROE ⓘ -52W High ⓘ -73.76% ($5.64)Perf Year ⓘ -57.03%
Cash/sh ⓘ -P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -52W Low ⓘ -2.63% ($1.52)Perf 3Y ⓘ -64.08%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 65.58%Gross Margin ⓘ -Volatility(W/M) ⓘ 8.66% 11%Perf 5Y ⓘ -88.82%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.18Perf 10Y ⓘ -90.86%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ -EPS Q/Q ⓘ 44.39%Profit Margin ⓘ -RSI (14) ⓘ 36.34Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ -Sales Q/Q ⓘ -SMA20 ⓘ -12.24% ($1.69)Beta ⓘ 1.5Target Price ⓘ $6
Payout ⓘ -Debt/Eq ⓘ -Earnings ⓘ -SMA50 ⓘ -25.11% ($1.98)Rel Volume ⓘ 0.28Prev Close ⓘ $1.54
Employees ⓘ 6LT Debt/Eq ⓘ -EPS/Sales Surpr. ⓘ -SMA200 ⓘ -42.55% ($2.58)Avg Volume(3M) ⓘ 0.01MPrice ⓘ $1.48
IPO ⓘ 2005/9/1Option/Short ⓘ No/YesTrades ⓘ 83Volume ⓘ 2,082Change ⓘ -3.9%
Company
XTLB XTLBX.T.L. Biopharmaceuticals Ltd ADR | NASD | Biotechnology Deep dive

🧪 This Israel-based clinical-stage biotech company focuses on autoimmune diseases and hematologic cancers. Its lead candidate, hCDR1, is preparing to enter Phase 2 clinical trials for systemic lupus erythematosus (SLE) and Sjögren's syndrome, while rHuEPO is also being developed to extend survival in multiple myeloma patients. The micro-cap stock is dual-listed on the U.S. Nasdaq and the Tel Aviv Stock Exchange.

Quote

Over the past 1 year, on the lower side

74% below its 1-year high.

Now $1.48
52w low$1.5252w high$5.64
52W Range0%
Volume ⓘ 2,082

Traded less than usual. That is 28% of its average volume.

D
Overall · many cautions
We judged 3 of the 8 questions below. 2 need caution.
No data for profitability, growth, valuation, outlook, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #524 of 598 in the industry

Based on market cap of $6M.

FAQ

FAQ

What kind of company is XTLB?

XTLB belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of XTLB?

The market cap of XTLB is approximately $6M, ranking 5,492 within its sector.

What is the 52-week high and low for XTLB?

XTLB has recorded a 52-week high of $5.64 and a low of $1.52.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels